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CASE REPORT

Loperamide cardio toxicity: a case report of turning bowels
and twisting points
Katherine Rizzolo MD,1 Ryan Best MD,2 Tammi Schaeffer DO, FACEP, FACMT, FAACT,3 John Erickson
MD FACP1
Department of Internal Medicine, Maine Medical Center, Portland, ME, 2Department of Critical Care Medicine, Maine
Medical Center, Portland, ME, 3Department of Emergency Medicine, Maine Medical Center, Portland, ME
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Introduction:

Loperamide is a synthetic mu-receptor agonist used for treating diarrhea. Recently, it has been illicitly
used for a euphoric high or to diminish symptoms of opiate withdrawal. In case reports, loperamide
abuse has been associated with cardiac arrhythmias, most notably, ventricular tachycardia and torsades
de pointes, presumably related to prolongation of the QTc.

Clinical findings: A 32-year-old male with a history of opioid use disorder presented unresponsive, and was found to have
polymorphic ventricular tachycardia, torsades de pointes, prolonged QTc and QRS, and transient left
ventricular dysfunction.
Diagnosis,
interventions,
and outcomes:

When his mental status cleared, the patient reported taking up to 40 pills (80 mg) of loperamide daily
with the intent of alleviating symptoms of opiate withdrawal. This misuse was believed to cause his QTc
prolongation, leading to cardiac toxicity and subsequent dysrhythmia. The patient initially required a
temporary pacing wire, which was removed on hospital day 3. He was discharged with a prescription
for suboxone and duloxetine, and he was connected with specialists to address his substance use
disorder.

Conclusions:

We describe a patient with cardiac toxicity associated with loperamide misuse. In the wake of the current
opioid epidemic, the occurrence of loperamide toxicity may increase. It is important for physicians to
understand and identify the life-threatening effects of loperamide toxicity to properly diagnose and
manage the condition.
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CASE PRESENTATION
A 32-year-old male with a history of opiate use
disorder presented to an outside emergency
department after being found unresponsive in
his running car. After 1 hour, he developed nonsustained ventricular tachycardia (VT) followed
by wide-complex bradycardia with first-degree
block. This bradycardia converted to polymorphic
VT requiring intravenous bicarbonate, singlesynchronous cardioversion, and amiodarone. He
then had a short, self-terminating episode of torsades
de pointes (Figure 1) followed by bradycardia with a
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QTc persistently over 600 msec and a QRS of 167
msec. He was transferred to the cardiac intensive
care unit of this hospital for immediate placement of
a temporary transvenous pacer with the purpose of
overdrive pacing.
The results of his initial exam only noted arrhythmia,
altered mental status, and agitation. The initial
lab results showed a leukocytosis of 14,300/uL,
troponin-T peak of 0.10 ng/mL (normal <0.01 ng/
mL), and brain natriuretic peptide of 1303 pg/
mL (normal <450 pg/dL). His urine toxicology
results reflected that the emergency department
administered midazolam. The echocardiogram
showed a reduced ejection fraction (30-35%) with
global wall motion abnormality.
1
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After the temporary wire was placed, the patient’s
mental status cleared. He reported finding internet
forums suggesting opioid-like effects with high
doses of loperamide, leading him to take up to 40
pills (80 mg) daily (recommended upper limit of
therapeutic dosing: 16 mg/daily). Twenty-four hours
after presentation, his loperamide level was 34 ng/
mL (normal limit: <5 ng/mL) and his desmethyl
loperamide level (a loperamide metabolite) was
250 ng/mL (therapeutic levels: <20 ng/mL).
By hospital day 2, his VT resolved, and his QTc and
QRS normalized, so the temporary pacemaker was
removed. On hospital day 3, a repeat transthoracic
echocardiogram showed normal systolic function.
He was discharged with suboxone, duloxetine, and
outpatient follow-up.

DISCUSSION
Loperamide is a synthetic opioid used to slow bowel
motility in diarrheal illness and is readily available
over the counter. It acts as a direct agonist at the
circular and intestinal muscles via the mu-opioid
receptor. At therapeutic doses, loperamide has
low oral bioavailability and nominally penetrates
the blood-brain barrier. Thus, it was believed to
have little potential for abuse.1 Recently, many
reports described cases in which loperamide was
misused recreationally or to alleviate symptoms of
withdrawal.

tachycardia, cardiac arrest, and death.1,5-11 Transient
left ventricular dysfunction is often observed with
stress- or tachycardia-induced cardiomyopathy.9,10
Notably, some cases reported that supratherapeutic
doses of loperamide can result in onset and an
increased duration of toxic effects that extend
beyond the drug’s reported half-life and duration of
action.11 The proposed mechanism is multifactorial
via antagonism at cardiac L-type calcium channels,
delayed rectifier potassium channels, and sodium
channel blockade. These effects lead to delayed
duration of action potentials, prolonged QRS, and
severe prolonged QTc. In addition, loperamide
inhibits the Nav1.5 sodium channel and the human
ether-a-go-go (hERG) rectifier potassium channel
in cloned human myocyte cells, affecting QRS
and QT prolongation, respectively.12 Interestingly,
sodium channel blockade may be dose-dependent,
as the phenomenon occurs only with high levels of
loperamide.
Diagnosis hinges upon clinical history and
the presence of arrhythmia at presentation.
Confirmatory lab testing may take 1-2 weeks.
Initial treatment should focus on establishing a
perfusing rhythm, which may require cardioversion
or temporary overdrive pacing with a pacing wire.
Isoproterenol has also been suggested but has
not been well studied. Naloxone has shown some
efficacy for reversing respiratory depression,
but it has ineffectively treated arrhythmias.6 With
aggressive supportive care, most patients improved
after loperamide was discontinued.5,11

Non-medical or non-prescribed use of loperamide
is increasing as information on the internet
regarding alternative uses continues to uptrend.2
One study analyzed the occurrence of the search
term “loperamide” with Google Trends.* The
analysis showed an increase in the use of the
search term “loperamide” from 2009 to 2015,
with an approximate 300% increase from 2011 to
2015 when combined with terms such as “high”
or “withdrawal.” The National Poison Database
System reported a 91% increase in intentional
loperamide exposures between 2010 and 2015.3 To
mitigate loperamide misuse, the US Food and Drug
Administration changed loperamide packaging to
blister packs to limit large-quantity purchases in
January 2018.4

Loperamide’s effect on QTc has been described
only in case reports; however, the effects of other
opiates on QTc prolongation have been studied
in greater detail.13 The predominant mechanism
involves inhibition of the lkr current.14 Specifically,
methadone prolongs QTc and is the leading cause
of medication-associated torsades de pointes.15
However, the effect of the methadone dose on QTc
prolongation is mixed.16,17 In contrast, buprenorphine
has been associated with fewer cases of torsades
de pointes and QTc prolongation.15 Oxycodone
has shown QTc prolongation that may be dosedependent, but to a lesser degree than methadone.14

Loperamide misuse has been associated with cardiac
dysrhythmias, such as ventricular fibrillation or

This case illustrates the potentially life-threatening
toxicity associated with loperamide misuse. As

* This feature reports a normalized line graph that reflects interest in a search topic as a proportion of all Google searches on all
topics during the specified time and location.
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Figure 1. Admission electrocardiogram illustrating torsades de pointes
opiate prescriptions are reduced in response to the
current opioid epidemic, loperamide misuse and
toxicity may increase. Physicians must be aware of
these dangers, as many dysrhythmias associated
with loperamide misuse can be unpredictable
and may be fatal without appropriate treatment.
Awareness of this condition will support the prompt
identification of toxicity and treatment of electrocardiac abnormalities, reducing mortality and
improving outcomes.
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